{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Papillary+Thyroid+Carcinoma&page=2",
    "query": {
      "condition": "Papillary Thyroid Carcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Papillary+Thyroid+Carcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T08:09:59.497Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03899792",
      "title": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Medullary Thyroid Cancer",
        "Infantile Myofibromatosis",
        "Infantile Fibrosarcoma",
        "Papillary Thyroid Cancer",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 36,
      "start_date": "2019-06-13",
      "completion_date": "2029-05",
      "has_results": true,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03899792"
    },
    {
      "nct_id": "NCT01502410",
      "title": "Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Hepatocellular Carcinoma",
        "Papillary Thyroid Cancer",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Liver Cancer",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Thyroid Cancer",
        "Recurrent Wilms Tumor and Other Childhood Kidney Tumors"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Years to 30 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-01",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2018-06-26",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502410"
    },
    {
      "nct_id": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 2,
      "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005842"
    },
    {
      "nct_id": "NCT06959641",
      "title": "XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Differentiated Thyroid Gland Carcinoma",
        "Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma",
        "Locally Advanced Thyroid Gland Follicular Carcinoma",
        "Locally Advanced Thyroid Gland Oncocytic Carcinoma",
        "Locally Advanced Thyroid Gland Papillary Carcinoma",
        "Metastatic Differentiated Thyroid Gland Carcinoma",
        "Metastatic Poorly Differentiated Thyroid Gland Carcinoma",
        "Metastatic Thyroid Gland Follicular Carcinoma",
        "Metastatic Thyroid Gland Oncocytic Carcinoma",
        "Metastatic Thyroid Gland Papillary Carcinoma",
        "Refractory Differentiated Thyroid Gland Carcinoma",
        "Refractory Poorly Differentiated Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Follicular Carcinoma",
        "Refractory Thyroid Gland Oncocytic Carcinoma",
        "Refractory Thyroid Gland Papillary Carcinoma",
        "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage III Thyroid Gland Follicular Carcinoma AJCC v8",
        "Stage III Thyroid Gland Papillary Carcinoma AJCC v8",
        "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v8",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Zanzalintinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2025-06-06",
      "completion_date": "2030-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 2,
      "location_summary": "Torrance, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06959641"
    },
    {
      "nct_id": "NCT03506048",
      "title": "Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Differentiated Thyroid Gland Carcinoma",
        "Thyroid Gland Follicular Carcinoma",
        "Thyroid Gland Papillary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2019-01-16",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-11-10",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03506048"
    },
    {
      "nct_id": "NCT07536412",
      "title": "Decision Aid Efficacy in Low Risk Thyroid Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Differentiated Thyroid Cancer (DTC)",
        "Papillary Thyroid Microcarcinoma",
        "Papillary Thyroid Carcinoma"
      ],
      "interventions": [
        {
          "name": "Decision Aid",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2026-05-15",
      "completion_date": "2029-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07536412"
    },
    {
      "nct_id": "NCT00519896",
      "title": "Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Thyroid Cancer",
        "Stage IVA Follicular Thyroid Cancer",
        "Stage IVA Papillary Thyroid Cancer",
        "Stage IVB Follicular Thyroid Cancer",
        "Stage IVB Papillary Thyroid Cancer",
        "Stage IVC Follicular Thyroid Cancer",
        "Stage IVC Papillary Thyroid Cancer",
        "Thyroid Gland Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2007-07",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-04-25",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00519896"
    },
    {
      "nct_id": "NCT00103155",
      "title": "Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiofrequency ablation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103155"
    },
    {
      "nct_id": "NCT04759911",
      "title": "Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Thyroid Gland Neoplasm",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Thyroid Gland Anaplastic Carcinoma",
        "Thyroid Gland Medullary Carcinoma",
        "Thyroid Gland Papillary Carcinoma",
        "Thyroid Gland Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-02-26",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04759911"
    },
    {
      "nct_id": "NCT02393690",
      "title": "Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Thyroid Gland Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Stage IV Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IV Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7",
        "Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Iodine I-131",
          "type": "RADIATION"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2015-05-04",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-06-10T08:09:59.497Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Newport Beach, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02393690"
    }
  ]
}